Eric Venker Sells 315,522 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 315,522 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the sale, the chief operating officer now owns 959,457 shares of the company’s stock, valued at $10,611,594.42. This trade represents a 24.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Stock Down 1.5 %

NASDAQ ROIV opened at $10.67 on Wednesday. Roivant Sciences Ltd. has a twelve month low of $9.96 and a twelve month high of $13.06. The stock has a market cap of $7.61 billion, a P/E ratio of -71.13 and a beta of 1.26. The company’s 50-day simple moving average is $10.78 and its 200 day simple moving average is $11.44.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ROIV. FMR LLC boosted its stake in shares of Roivant Sciences by 0.3% in the 4th quarter. FMR LLC now owns 49,301,583 shares of the company’s stock valued at $583,238,000 after purchasing an additional 156,527 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. State Street Corp boosted its position in Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares in the last quarter. Patient Square Capital LP grew its stake in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock worth $147,638,000 after buying an additional 251,535 shares during the last quarter. Finally, Two Seas Capital LP increased its holdings in shares of Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock worth $120,285,000 after buying an additional 442,914 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $17.10.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.